Article Abstract

Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management

Authors: Yayi He, Caicun Zhou


Lung cancer is the most common cancer in the world (1-3). In the past 10 years, studies have shown that tyrosine kinase inhibitors (TKIs), such as gefitinib, afatinib, and crizotinib, provide significant benefits to advanced non-small cell lung cancer (NSCLC) patients (4,5). NSCLC with positive epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations can achieve longer progression-free survival (PFS) and a higher life quality through treatment with TKIs (4,5).